Cart
sales@molnova.com
Ozagrel hydrochloride
CAS No. 78712-43-3
Ozagrel hydrochloride( —— )
Catalog No. M15964 CAS No. 78712-43-3
Ozagrel HCl is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 39 | In Stock |
|
| 25MG | 67 | In Stock |
|
| 50MG | 106 | In Stock |
|
| 100MG | 160 | In Stock |
|
| 200MG | 241 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOzagrel hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionOzagrel HCl is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet.
-
DescriptionOzagrel HCl is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetThrombin
-
RecptorThromboxane A2 synthetase
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number78712-43-3
-
Formula Weight264.71
-
Molecular FormulaC13H12N2O2·HCl
-
Purity>98% (HPLC)
-
SolubilityEthanol: 6 mg/mL (22.66 mM); Water: 53 mg/mL (200.21 mM); DMSO: 53 mg/mL (200.21 mM)
-
SMILESC1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ishitsuka Y, et al. J Pharmacol Sci, 2009, 111(2), 211-215.
molnova catalog
related products
-
AZD-8165
AZD-8165 is a potent, selective and oral thrombin inhibitor for treatment of thrombosis.
-
Protamine sulfate
Protamine sulfate is a polycationic peptide that serves as an antiheparin agent. This compound can neutralize the anticoagulant action of heparin and enhance lipid-mediated gene transfer.
-
Ximelagatran
Ximelagatran, a direct thrombin inhibitor, can be taken orally and acts solely by inhibiting the actions of thrombin. Ximelagatran is converted to the active agent melagatran in vivo.
